Financial News
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
March 09, 2023 at 07:53 AM EST
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots ↗
Today 10:35 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
